1. Home
  2. ENTX vs LICN Comparison

ENTX vs LICN Comparison

Compare ENTX & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • LICN
  • Stock Information
  • Founded
  • ENTX 2010
  • LICN 2004
  • Country
  • ENTX Israel
  • LICN China
  • Employees
  • ENTX N/A
  • LICN N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • LICN
  • Sector
  • ENTX Health Care
  • LICN
  • Exchange
  • ENTX Nasdaq
  • LICN Nasdaq
  • Market Cap
  • ENTX 90.2M
  • LICN 8.7M
  • IPO Year
  • ENTX 2018
  • LICN 2023
  • Fundamental
  • Price
  • ENTX $2.55
  • LICN $0.07
  • Analyst Decision
  • ENTX Strong Buy
  • LICN
  • Analyst Count
  • ENTX 1
  • LICN 0
  • Target Price
  • ENTX $10.00
  • LICN N/A
  • AVG Volume (30 Days)
  • ENTX 86.5K
  • LICN 11.8M
  • Earning Date
  • ENTX 03-07-2025
  • LICN 12-31-2024
  • Dividend Yield
  • ENTX N/A
  • LICN N/A
  • EPS Growth
  • ENTX N/A
  • LICN 36.90
  • EPS
  • ENTX N/A
  • LICN 0.28
  • Revenue
  • ENTX $99,000.00
  • LICN $41,929,000.00
  • Revenue This Year
  • ENTX N/A
  • LICN N/A
  • Revenue Next Year
  • ENTX N/A
  • LICN N/A
  • P/E Ratio
  • ENTX N/A
  • LICN $0.30
  • Revenue Growth
  • ENTX 607.14
  • LICN 24.86
  • 52 Week Low
  • ENTX $0.71
  • LICN $0.06
  • 52 Week High
  • ENTX $3.35
  • LICN $2.44
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 61.93
  • LICN 22.59
  • Support Level
  • ENTX $2.00
  • LICN $0.06
  • Resistance Level
  • ENTX $2.62
  • LICN $0.08
  • Average True Range (ATR)
  • ENTX 0.18
  • LICN 0.02
  • MACD
  • ENTX 0.01
  • LICN 0.03
  • Stochastic Oscillator
  • ENTX 96.77
  • LICN 12.06

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About LICN Lichen China Limited

Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.

Share on Social Networks: